[ad_1]
Dr Anthony Fauci said UK health regulators did not review trial data as carefully as the US Food and Drug Administration before approving the use of Pfizer’s coronavirus vaccine, according to a report.
“The way the FDA is, our FDA is doing it, is the right way,” Fauci, director of the National Institute of Allergy and Infectious Diseases, told Fox News, according to CNN.
“We’re really looking at the data very carefully to assure the American public that this is a safe and effective vaccine,” Fauci said.
“I think if we did less, we would add to the already existing reluctance on the part of many people to take the vaccine because they are concerned about safety or because they fear that we have gone too fast.” , he added.
America’s leading infectious disease doctor has said it’s important Americans feel good about a potential vaccine against the deadly virus.
“So it’s almost a damn if you do it and you are damn if you don’t, because if you go fast and do it superficially, people won’t want to get the shot,” he said. -he declares.
“We have the gold standard of a regulatory approach with the FDA. The UK didn’t do it so carefully and it got a few days early, ”he said. “I don’t think it makes a lot of difference. We will be there. We will be there very soon, ”added Fauci.
The chief doctor’s comments came after the White House said it was not notified before Britain gave the go-ahead – an unexpected move that put it at least a week before the United States in the distribution of the vaccine developed by Pfizer, an American drug manufacturer, and BioNTech in Germany.
The FDA is not supposed to consider authorizing emergency use of the vaccine until December 10.
President Trump demanded to know why the FDA was not moving faster to approve the shot, according to Politico.
FDA Commissioner Stephen Hahn has defended the agency’s review process, saying careful scrutiny is needed to ensure the public believes in the safety and efficacy of the vaccine.
Hahn told the Wall Street Journal that the FDA had 150 people working days, nights and weekends to review test data submitted by Pfizer and BioNTech.
“We are aware that there is a problem in the United States regarding vaccine hesitancy. Concerns have been raised about how quickly COVID-19 vaccines have been developed, ”Hahn told the Journal.
“It will meet our standard of safety and efficiency that the American people have trusted,” he added.
[ad_2]
Source link